TNF-α Gene knockout in triple negative breast cancer cell line induces apoptosis

International Journal of Molecular Sciences

Volumn 14, Issue 1, 2013, Pages 411-420

  Pileczki, Valentina ^a   Braicu, Cornelia ^a,b   Gherman, Claudia D ^a,c   Berindan Neagoe, Ioana ^a,b  

^a IULIU HATIEGANU UNIVERSITY OF MEDICINE AND PHARMACY   (Romania)

^b Cancer Institute Ion Chiricuta Cluj Napoca   (Romania)

^c First Surgical Clinic   (Romania)

Author keywords

Apoptosis; Cell signaling pathways; Gene therapy; RNA interference

Indexed keywords

SMALL INTERFERING RNA; STRESS ACTIVATED PROTEIN KINASE; TUMOR NECROSIS FACTOR ALPHA;

ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; BAK 1 GENE; CANCER CELL CULTURE; CANCER CELL DESTRUCTION; CANCER GENE THERAPY; CELL FATE; CELL SURVIVAL; CELL VIABILITY; CONTROLLED STUDY; DOWN REGULATION; ENZYME ACTIVATION; FLOW CYTOMETRY; GENE; GENE EXPRESSION PROFILING; GENE IDENTIFICATION; GENE INACTIVATION; GENE SILENCING; GENE TARGETING; HUMAN; HUMAN CELL; IN VITRO STUDY; INTRACELLULAR SIGNALING; NONVIRAL GENE THERAPY; POLYMERASE CHAIN REACTION; RNA INTERFERENCE; TRIPLE NEGATIVE BREAST CANCER; TUMOR NECROSIS FACTOR ALPHA GENE; UPREGULATION; CELL MOTION; CELL PROLIFERATION; FEMALE; GENE EXPRESSION REGULATION; GENE REGULATORY NETWORK; GENETICS; METABOLISM; NECROSIS; PATHOLOGY; TIME; TUMOR CELL LINE;

APOPTOSIS; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; CELL SURVIVAL; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE KNOCKOUT TECHNIQUES; GENE REGULATORY NETWORKS; HUMANS; NECROSIS; RNA, SMALL INTERFERING; TIME FACTORS; TRIPLE NEGATIVE BREAST NEOPLASMS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84872176009     PISSN: 16616596     EISSN: 14220067     Source Type: Journal    
DOI: 10.3390/ijms14010411     Document Type: Article

References (31)

1. Takeshita, F.; Ochiya, T.; Zhang, L.; Hao, C.; Dong, G.; Tong, Z. Analysis of clinical features and outcome of 356 triple-negative breast cancer patients in China. Breast Care 2012, 7, 13-17.
2. Griffiths, C.L.; Olin, J.L. Triple negative breast cancer: A brief review of its characteristics and treatment options. J. Pharm. Pract. 2012, 25, 319-323.
3. Ossovskaya, V.; Wang, Y.; Budoff, A.; Xu, Q.; Lituev, A.; Potapova, O.; Vansant, G.; Monforte, J.; Daraselia, N. Exploring molecular pathways of triple-negative breast cancer. Genes Cancer 2011, 2, 870-879.
4. Brown, E.R.; Charles, K.A.; Hoare, S.A.; Rye, R.L.; Jodrell, D.I.; Aird, R.E.; Vora, R.; Prabhakar, U.; Nakada, M.; Corringham, R.E.; et al. A clinical study assessing the tolerability and biological effects of infliximab, a TNF-a inhibitor, in patients with advanced cancer. Ann. Oncol. 2008, 19, 1340-1346.
5. Balkwill, F. TNF-α in promotion and progression of cancer. Cancer Metastasis Rev. 2006, 25, 409-416.
6. Madhusudan, S.; Foster, M.; Muthuramalingam, S.R.; Braybrooke, J.P.; Wilner, S.; Kaur, K.; Han, C.; Hoare, S.; Balkwill, F.; Talbot, D.C.; et al. A phase II study of Etanercept (Enbrel), a tumor necrosis factor inhibitor in patients with metastatic breast cancer. Clin. Cancer Res. 2004, 10, 6528-6534.
7. Hwang, J.R.; Jo, K.; Lee, Y.; Sung, J.B.; Park, Y.W.; Lee, J.H. Upregulation of CD9 in ovarian cancer is related to the induction of TNF-a gene expression and constitutive NF-κB activation. Carcinogenesis 2012, 33, 77-83.
8. Kulbe, H.; Thompson, R.; Wilson, J.L.; Robinson, S.; Hagemann, T.; Fatah, R.; Gould, D.; Ayhan, A.; Balkwill, F. The inflammatory cytokine tumor necrosis factor-α generates an autocrine tumor-promoting network in epithelial ovarian cancer cells. Cancer Res. 2007, 67, 585-592.
9. He, S.; Zhang, D.; Cheng, F.; Gong, F.; Guo, Y. Applications of RNA interference in cancer therapeutics as a powerful tool for suppressing gene expression. Mol. Biol. Rep. 2009, 36, 2153-2163.
10. Cuccato, G.; Polynikis, A.; Siciliano, V.; Graziano, M.; di Bernardo, M.; di Bernardo, D. Modeling RNA interference in mammalian cells. BMC Syst. Biol. 2011, 5, 19.
11. Chen, S.H.; Zhaori, G. Potential clinical applications of siRNA technique: Benefits and limitations. Eur. J. Clin. Invest. 2010, 41, 221-232.
12. Lares, M.R.; Rossi, J.J.; Ouellet, D.L. RNAi and small interfering RNAs in human disease therapeutic applications. Trends Biotechnol. 2010, 28, 570-579.
13. Grimm, D.; Kay, M.A. Therapeutic application of RNAi: Is mRNA targeting finally ready for prime time? J. Clin. Invest. 2007, 117, 3633-3641.
14. Simmons, O.; Maples, P.B.; Senzer, N.; Nemunaitis, J. Ewing's Sarcoma: Development of RNA interference-based therapy for advanced disease. ISRN Oncol. 2012, 2012, 247657.
15. Aagaard, L.; Rossi, J.J. RNAi Therapeutics: Principles, prospects and challenges. Adv. Drug Deliv. Rev. 2007, 59, 75-86.
16. Takeshita, F.; Ochiya, T. Therapeutic potential of RNA interference against cancer. Cancer Sci. 2006, 97, 689-696.
17. Petrova, N.S.; Chernikov, I.V.; Meschaninova, M.I.; Dovydenko, I.S.; Venyaminova, A.G.; Zenkova, M.A.; Vlassov, V.V.; Chernolovskaya, E.L. Carrier-free cellular uptake and the gene-silencing activity of the lipophilic siRNAs is strongly affected by the length of the linker between siRNA and lipophilic group. Nucleic Acids Res. 2012, 40, 2330-2344.
18. Zhang, J.D.; Koerner, C.; Bechtel, S.; Bender, C.; Keklikoglou, I.; Schmidt, C.; Irsigler, A.; Ernst, U.; Sahin, O.; Wiemann, S.; et al. Time-resolved human kinome RNAi screen identifies a network regulating mitotic-events as early regulators of cell proliferation. PLoS One 2011, 6, e22176.
19. Kumar, P.S.; Shiras, A.; Das, G.; Jagtap, J.C.; Prasad, V.; Shastry, P. Differential expression and role of p21cip/waf1 and p27kip1 in TNF-α-induced inhibition of proliferation in human glioma cells. Mol. Cancer 2007, 6, 42.
20. Hagemann, T.; Wilson, J.; Kulbe, H. TNF-α dependent increased c-Jun and NF-κB activity in tumour cell lines upon co-cultivation with macrophages. J. Immunol. 2005, 175, 1197-1205.
21. Wu, Y.; Zhou, B.P. TNF-a/NF-kB/Snail pathway in cancer cell migration and invasion. Br. J. Cancer 2010, 102, 639-644.
22. Szlosarek, P.W.; Grimshaw, M.J.; Kulbe, H.; Wilson, J.L.; Wilbanks, G.D.; Burke, F.; Balkwill, F.R. Expression and regulation of tumor necrosis factor alpha in normal and malignant ovarian epithelium. Mol. Cancer Ther. 2006, 5, 382-390.
23. Szlosarek, P.; Charles, K.A.; Balkwill, F.R. Tumour necrosis factor-α as a tumour promoter. Eur. J. Cancer 2006, 42, 745-750.
24. Egberts, J.H.; Cloosters, V.; Noack, A.; Schniewind, B.; Thon, L.; Klose, S.; Kettler, B.; von Forstner, C.; Kneitz, C.; Tepel, J.; et al. Anti-tumor necrosis factor therapy inhibits pancreatic tumor growth and metastasis. Cancer Res. 2008, 68, 1443-1450.
25. Setlur, S.R.; Royce, T.E.; Sboner, A.; Mosquera, J.M.; Demichelis, F.; Hofer, M.D.; Mertz, K.D.; Gerstein, M.; Rubin, M.A. Integrative microarray analysis of pathways dysregulated in metastatic prostate cancer. Cancer Res. 2007, 67, 10296-10303.
26. Lessard, L.; Karakiewicz, P.I.; Bellon-Gagnon, P.; Alam-Fahmy, M.; Ismail, H.A.; Mes-Masson, A.M.; Saad, F. Nuclear localization of nuclear factor-κB p65 in primary prostate tumors is highly predictive of pelvic lymph node metastases. Clin. Cancer Res. 2006, 12, 5741-5745.
27. Sprowl, J.A.; Reed, K.; Armstrong, S.R.; Lanner, C.; Guo, B.; Kalatskaya, I.; Stein, L.; Hembruff, S.L.; Tam, A.; Parissenti, A.M. Alterations in tumor necrosis factor signaling pathways are associated with cytotoxicity and resistance to taxanes: A study in isogenic resistant tumor cells. Breast Cancer Res. 2012, 14, R2.
28. Soares, R.; Meireles, M.; Rocha, A.; Pirraco, A.; Obiol, D.; Alonso, E.; Joos, G.; Balogh, G. Maitake (D Fraction) mushroom extract induces apoptosis in breast cancer cells by BAK-1 gene activation. J. Med. Food 2011, 14, 563-572.
29. Chittenden, T.; Harrington, E.A.; O'Connor, R.; Flemington, C.; Lutz, R.J.; Evan, G.I.; Guild, B.C. Induction of apoptosis by the Bcl-2 homologue Bak. Nature 1995, 374, 733-736.
30. Montagut, C.; Tusquets, I.; Ferrer, B.; Corominas, J.M.; Bellosillo, B.; Campas, C.; Suarez, M.; Fabregat, X.; Campo, E.; Gascon, P.; et al. Activation of nuclear factor-κB is linked to resistance to neoadjuvant chemotherapy in breast cancer patients. Endocr. Relat. Cancer 2006, 13, 607-616.
31. Lee, H.Y.; Youn, S.W.; Kim, J.Y.; Park, K.W.; Hwang, C.I.; Park, W.Y.; Oh, B.H.; Park, Y.B.; Walsh, K.; Seo, J.S.; et al. FOXO3a turns the tumor necrosis factor receptor signaling towards apoptosis through reciprocal regulation of c-Jun N-Terminal Kinase and NF-κB. Arterioscler. Thromb. Vasc. Biol. 2008, 28, 112-120.